Organic molecular crystals can respond to external stimuli such as heat, light, and mechanical force, making them attractive candidates for next-generation functional materials. However, predicting ...
Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced ...
IND authorization paves the way for initiation of GT-02287 Phase 2 clinical development in the U.S., expected during 3Q26FDA’s decision follows ...
Artificial intelligence is fundamentally reshaping lending structures beyond mere operational improvements. This shift moves ...
The world’s most valuable assets are stored on rows of servers in giant, anonymous buildings. And they can be stolen.
Manufacturers are entering a new phase of digital transformation where artificial intelligence is moving from isolated pilots ...
Blood-brain barrier drug delivery reached a landmark: the FDA’s March 2026 accelerated approval of Denali Therapeutics’ ...
(Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN), a clinical stage biotechnology company developing immune-modulating therapies ...
Exclusive: Experts say Brexit has led to delays in the launch of clinical trials and increased costs for multiple drugs. They ...
The Colorful iGame X870E VULCAN OC V14 combines serious AM5 overclocking hardware with an eye-watering price tag of Rs 123000 ...
California continues to solidify its role as a national leader in regulating “AI” in the employment context. On June 25, 2026, Governor Gavin ...
IND authorization paves the way for initiation of GT-02287 Phase 2 clinical development in the U.S., expected during 3Q26 FDA's decision follows positive Phase 1 results for GT-02287 in both healthy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results